Praluent — Cigna

Atherosclerotic Cardiovascular Disease (ASCVD)

Initial criteria

Patient has one or more of the following (a–f): a) previous myocardial infarction or history of acute coronary syndrome; OR b) angina (stable or unstable); OR c) past history of stroke or transient ischemic attack; OR d) coronary artery disease; OR e) peripheral arterial disease; OR f) patient has undergone a coronary or other arterial revascularization procedure; AND
Patient meets ONE of the following (a or b): a) BOTH of the following [(1) and (2)]: (1) patient has tried one high-intensity statin therapy (atorvastatin ≥ 40 mg daily or rosuvastatin ≥ 20 mg daily, as single-entity or combination product) for ≥ 8 continuous weeks; AND (2) LDL-C level after this treatment remains ≥ 55 mg/dL; OR b) patient determined statin intolerant by having statin-related rhabdomyolysis OR having skeletal muscle symptoms with both atorvastatin and rosuvastatin trials resolving upon discontinuation.

Patient currently receiving Praluent and, according to the prescriber, has experienced a response to therapy (e.g., decrease in LDL-C, total cholesterol, non-HDL-C, or apolipoprotein B levels).

1 year